FORMULATION, DEVELOPMENT AND OPTIMIZATION OF SUSTAINED RELEASE DELIVERY SYSTEM OF ANTI-PLATELET DRUGS

Abstract

Antiplatelet medications currently on the market interfere with one or more phases in the platelet release and aggregation process, leading to a meaningful decrease in thrombosis risk that cannot be separated from an elevated risk of bleeding. Understanding that under physiological conditions, 1011 platelets are created daily-a quantity that can rise up to 10-fold during times of greater need—is crucial when thinking about antiplatelet medications.